Estimated first-year savings ranged from $33 to $166 per member.
The FDA has accepted for review its New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin]) injection.
WHO criteria better than National Osteoporosis Foundation criteria for identifying men who would benefit from drug treatment.
The FDA has found no clear evidence of increased cardiovascular risks associated with olmesartan medoxomil in patients with diabetes.
The FDA now requires a general warning in the drug labeling of all approved testosterone products regarding the risk of venous blood clots.
Please login or register first to view this content.